Good morning, and welcome to our first quarter 2026 earnings call. Joining me today are Ashley McEvoy, President and Chief Executive Officer; Flavia Pease, Chief Financial Officer; and Eric Benjamin, Chief Operating Officer.

On the call this morning, we will be discussing Insulet's first quarter results along with our financial outlook for the second quarter and full year 2026. With that, let me start our prepared remarks by reminding everyone that we will make forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially. Please refer to today's press release and our SEC filings, including our most recent Form 10-K and Form 10-Q, for a discussion of these risks.

We undertake no obligation to update any forward-looking statements. In addition, on today's call, non-GAAP financial measures will be used to help investors understand Insulet's ongoing business performance, including adjusted gross profit, adjusted operating income, adjusted EPS, free cash flow, and constant currency revenue, which is revenue growth excluding the effect of foreign exchange.

Reconciliations of the non-GAAP financial measures being discussed today to the comparable GAAP financial measures are included in the accompanying investor presentation and are available in our earnings release issued this morning, both of which are available on our website. Additionally, unless otherwise stated, all financial commentary regarding dollar and percentage changes will be on a year-over-year reported basis, with the exception of revenue growth rates, which will be on a year-over-year constant currency basis.

During the Q&A session this morning, Ashley, Flavia, Eric, and myself will be available to address any questions. Now I'd like to turn the call over to Ashley.

Ashley?

Thank you, Clare, and good morning, everyone. We're pleased to report a strong start to 2026 with continued growth momentum, robust margin expansion, and disciplined execution of the strategic priorities we shared at Investor Day.

Our first quarter performance clearly reflects the opportunity in our large and underpenetrated markets, the strength of our differentiated technology and compelling clinical outcomes, the scalability of our recurring revenue business model, and the deep expertise and commitment of our teams around the world to finding a better way for people living with diabetes. We also made notable progress on our strategic priorities, which are to accelerate innovation that improves outcomes and unlocks new segments, develop our core markets as the category leader, strengthen our commercial capabilities, build a world-class team to enable our growth ambition, and leverage our financial strength to invest in and scale our business profitably.

In the first quarter, we achieved 30% revenue growth, including 28% in the US and 45% internationally. We continued to expand our customer base through new customer starts and enjoy strong retention and loyalty among our Podders globally.

Leveraging our strong revenue growth, we expanded adjusted operating margin by 110 basis points year-over-year. Adjusted EPS growth of approximately 40% was driven by our robust top-line growth and margin expansion and the benefits of our first quarter share repurchase.

This performance reinforces our confidence in the financial growth algorithm we laid out last year and in our strategy to capture the significant opportunity ahead of us as the market leader and primary driver of category growth in the fast-growing global AID market. As a result, we are raising our full year 2026 total company revenue growth guidance from 20% to 22% to 21% to 23%.

Flavia will share more details on our performance and outlook shortly, but let me first walk you through how we are developing our key markets, driving performance, and advancing our strategic priorities. Starting with the US, our growth this quarter was strong, reinforcing our market leadership.

We grew new customer starts year-over-year led by strong momentum in AID adoption for Type 2 and benefited from positive pricing. We did experience greater than normal seasonality, which we believe was driven by the annual reset of deductibles impacting patient copays and coinsurance.

These factors contributed to what appears to be a slower start to the year across the US diabetes category. Improving month-on-month trends over the course of the quarter and into April suggest this was a temporary headwind, and we remain confident in our US outlook for the full year.

Our upcoming integration with the Libre 3+ sensor this quarter will unlock the benefits of Omnipod 5 for the nearly 450,000 people with diabetes currently using the Libre 3+ sensor. In US Type 1, we continue to extend our leadership and drive increased penetration, with solid growth in our customer base both annually and sequentially.

Commercially, we are upskilling our field force to strengthen our messaging on clinical performance in the field, and we're deploying tools to optimize physician targeting and conversion while expanding reach and frequency. I remain confident in the opportunity to continue to move people with Type 1 diabetes from MDI to AID and drive increased penetration.

In US Type 2, we continue to expand the category and accelerate adoption from those using MDI. As expected, our Type 2 customer base grew rapidly over the prior year, supported by our prescriber education initiatives and the ADA guideline update, which established AID as the standard of care.

We remain confident in the trajectory for US Type 2 AID adoption and in expanding our market leadership position. Notably, Omnipod's first-mover advantage gives us a head start in understanding the nuances of this market and in designing targeted initiatives to eliminate the barriers for adoption.

For example, access and affordability are even more important for adoption in Type 2 than in Type 1. In fact, our ongoing efforts to increase access and remove prior authorization requirements generated a 4% net access improvement in the first quarter, benefiting an additional 16 million lives.

We continue to see a vast opportunity to bring meaningful improvement in both clinical outcomes and quality of life to the millions of people with Type 2 diabetes. Moving outside the US, our international business delivered another standout quarter, driving significant profitable growth and recording our third consecutive quarter of growth above 40%.

We achieved 45% constant currency revenue growth supported by continued strong year-over-year and sequential growth in new customer starts, as well as positive price mix from the ongoing conversion from DASH to Omnipod 5. We are generating robust growth across our largest and most established European markets, including the UK, France, and Germany, all of which delivered strong first quarter new customer starts driven in part by our focus on new prescriber activations.

In the UK, we achieved record NCS three years into our launch, reflecting the success of our strategy to deepen penetration internationally. We also continue to expand access and reinforce the value of Omnipod 5.

In Canada, for example, we secured improved reimbursement and new coverage for Omnipod 5 across four provinces, further fueling our growth. We now have reimbursement approval for 85% of the Canadian market.

Looking ahead, we remain on track to launch Omnipod 5 in Spain in the second half of the year. Spain has more than 200,000 people with Type 1 diabetes, a high rate of CGM adoption, and one of the lowest levels of AID penetration in our European markets.

In the second half of this year, we plan to launch Libre 3+ in Germany and Canada, allowing us to bring Omnipod 5 to new populations, as Libre 2+ is not available with a pump in either of these markets. Critically, our rapidly growing scale internationally continues to drive operating leverage and significant margin expansion.

Our strategy to deepen our penetration in our largest and most established markets is working, and our execution continues to exceed expectations. We continue to see the AID category expand globally.

While our success is attracting competition, this further validates and raises awareness of AID and Omnipod, the most recognized brand in the category. We believe this dynamic is good for the category and good for Insulet.

We are uniquely positioned to meet that worldwide demand at scale, and we are investing in accelerating innovation, strengthening our commercial capabilities, developing our markets, building a world-class team, and scaling our global operations to ensure we continue to benefit disproportionately from category growth. Let me unpack these priorities further.

Innovation remains the core driver of our growth strategy, beginning with this year's launch of our second-generation algorithm coupled with our Libre 3+ sensor integration and the broader rollout of Omnipod Discover, our new data insights platform. First, let me walk through the specific improvements behind the meaningful Omnipod 5 algorithm enhancements we're launching this quarter.

In our simulated analysis, switching the target glucose setting from 120 milligrams per deciliter to our new 100 milligrams per deciliter option delivered an approximately 5% improvement in time in range. This is better performance through a simple setting change with no added user burden.

Additionally, we improved the algorithm performance so it now increases the amount of time users spend in automated mode with fewer interruptions during extended high glucose events. This has been a pain point for prescribers and Podders.

We are pairing these two launches with an increased focus on clinical education to ensure prescribers understand the strong clinical efficacy and safety profile of Omnipod 5. Algorithm innovation will continue to be a key R&D focus.

In fact, we are increasing investment this year to advance our next generation of products. We are making strong progress on our sixth-generation Omnipod paired with our third-generation algorithm, which is planned to launch in 2027.

We are sharing data from STRIVE, our Omnipod 6 pivotal study, at ADA in June, which will demonstrate continued improvement in automation and clinical outcomes. This gives us confidence in the durability of our market leadership.

Next up is our transformative approach to unlock the Type 2 diabetes segment. We are making progress on what we believe will be the first-of-its-kind, truly fully closed-loop system for people with Type 2 diabetes.

We are encouraged by the results from our feasibility study that we presented at ATTD, which highlighted 68% time in range with no boluses. I'm very pleased to share that just last week, we enrolled our first participant in EVOLVE, our pivotal study to support FDA filing next year and launch in 2028.

These new product investments are designed to help us deliver better outcomes, enhance the user experience, and unlock new market segments, accelerating the shift to simpler, more intuitive insulin delivery and extending our leadership. We also recognize that as this category grows, innovation alone is not enough, and we are investing in building a top-notch team and commercial capabilities to expand the AID market, fortify our competitive position, and drive rapid adoption.

As part of that effort, we recently appointed Mike Panos as Chief Commercial Officer to lead our global commercial organization. Mike brings a proven track record of building and scaling world-class sales teams, driving market expansion, and delivering sustained double-digit growth across leadership categories.

Our investments in our brand are also delivering unique commercial value. We have the most recognized brand in the category, which continues to bring in new users and generate traction with prescribers that our sales force doesn't actively target.

We regularly activate our number one brand to increase category and brand awareness, and this quarter, Omnipod's feature appearance on the TV show Scrubs was a resounding success at raising awareness and amplifying representation. After the show, our inboxes were flooded with stories about how meaningful and moving it is to see people with diabetes show up like this, living their lives daily with ease.

These moments also drive action, like Michelle, who has Type 1 diabetes and reached out to one of our support specialists online after watching the episode. Michelle had a script for Omnipod written three years ago, but never moved forward.

With this nudge, we successfully re-engaged her and got her started on Omnipod. Market development remains a top priority.

In addition to the progress on market-specific initiatives that I highlighted earlier, we are seeing strong traction with our global KOL engagement and professional education efforts. We doubled the size of our US peer-to-peer education program in 2025 and expanded it by more than 50% year-over-year this quarter.

In Spain, we are investing in key opinion leader education well ahead of the advance to accelerate adoption. As I mentioned earlier, our efforts to improve access, secure new coverage, and strengthen our value to payers are yielding tangible benefits to our growth and sustaining our market-leading US coverage of over 90%.

These efforts also support the maintenance of our preferred position in the pharmacy channel amid increasing competitive activity, which validates the value of our pioneering pharmacy pay-as-you-go model. Notably, based on the pricing activity we have seen in this channel to date, we continue to expect rational and disciplined pricing and rebate behavior.

We remain focused on educating payers on the clinical and economic value of Omnipod to ensure broad, high-quality access in all markets. Finally, scaling global manufacturing and operations continues to be a priority.

We remain focused on quality, reliability, and customer safety. Our team rapidly responded to execute the voluntary medical device correction in March and implemented targeted fixes for the applicable manufacturing process.

Manufacturing disposable, sophisticated electromechanical devices at consumer scale and medical quality is a complex process. We continue to believe that our ability to meet the unique manufacturing demands of tubeless AID remains a source of strategic and financial advantage.

We have market-leading gross margins driven by our ongoing manufacturing productivity improvements. We continue to ramp our capacity and automation investments in Acton, Malaysia, and Costa Rica to support future growth.

In summary, we are executing on each pillar of our strategy: accelerating innovation, developing our markets, strengthening commercial capabilities, building a world-class team, and scaling global growth profitably. Omnipod continues to be the market leader and the disproportionate driver of AID category growth in the US and abroad.

Our investments are focused on extending our leadership by deepening differentiation across our platform while continuing to lighten the burden for people living with diabetes. Our strong results this quarter are a testament to the strength of our position, our execution, and our attractive recurring revenue business model.

I remain confident in our outlook for the year, our strategic path forward, and our ability to deliver sustained, profitable growth for shareholders and better outcomes for all of our Podders. With that, I'll turn the call over to Flavia.

Thank you, Ashley, and good morning, everyone. As Ashley highlighted, the Insulet team delivered a strong start to the year.

First quarter total revenues of $762 million increased 34% on a reported basis and 30% on a constant currency basis, and total Omnipod revenue grew 33% on a constant currency basis. In Q1 of 2026, our global customer base grew nearly 25% year-over-year, driven by increased adoption of Omnipod 5 across both the US and international markets.

Global new customer starts also increased versus the prior year period, with growth both in the US and internationally. MDI conversions continue to be the primary source of new customer starts, and we expect this to remain the case given the significant underpenetration across our core markets, including US Type 1, US Type 2, and international Type 1 diabetes.

Globally, utilization and annualized retention rates remained similar to the prior year period. Now turning to our performance in greater detail.

US Omnipod revenue grew 28% in the first quarter, exceeding the high end of our guidance range, driven by continued demand for Omnipod 5 across both Type 1 and Type 2. The quarter included a benefit of approximately $10 million in revenue related to the timing of certain distributor orders, which we expect to be consumed in the second quarter.

Excluding this impact, underlying US revenue growth was approximately 26%, coming in at the high end of our guidance. First quarter US new customer starts increased year-over-year, but declined sequentially.

As Ashley noted, we attribute the sequential decline to seasonality driven by the annual reset of deductibles, which impacts patient copays and coinsurance. This effect was less evident in 2025 given that we were in the earlier stages of the Type 2 launch.

Importantly, we saw US new customer starts ramp through the quarter, and that momentum has continued into the second quarter. International Omnipod strength continued in the first quarter, with revenue growth of 59% on a reported basis and 45% on a constant currency basis.

Volume remains the primary driver of international Omnipod growth, supported by customer expansion across both established and newly launched markets, along with favorable price mix benefits from the transition off DASH. Continuing down the P&L, our first quarter GAAP gross margin was 69.5% and included approximately $12 million of expenses associated with our medical device correction.

Our adjusted gross margin was 71%, down 90 basis points year-over-year. During the quarter, we incurred some increased excess and obsolescence costs as we transitioned to new pod configurations that position us to support Libre 3+ sensor integration and upcoming algorithm enhancements.

These costs negatively impacted adjusted gross margin by more than 150 basis points. After adjusting for this impact, gross margin performance in the quarter was driven by strong top-line growth, continued manufacturing productivity gains, and positive pricing.

Turning to OpEx, we continue to invest with intention to both maintain and extend our leadership while remaining disciplined in how we deploy capital. During the quarter, we ramped R&D investments to support our innovation roadmap and advance key clinical development programs, including Omnipod 6 and fully closed loop for Type 2.

These investments position us to continue delivering meaningful innovation over the long run. We also increased SG&A investments as we continue to prioritize market development initiatives to unlock AID penetration and demand generation efforts.

We expect to continue ramping investments in sales and marketing as we expand our sales force during the second quarter and prepare for upcoming product launches, including Libre 3+ integration and our latest algorithm enhancements. These investments expand our commercial capacity, broaden HCP coverage, and enable us to drive additional new customer starts.

First quarter adjusted operating margin expanded 110 basis points to 17.5%, driven by strong top-line growth and SG&A leverage. Our financial strength allows us to continue to invest for future growth while delivering margin expansion.

First quarter net interest expense was $9.8 million, an increase of $11 million, primarily driven by our prior year debt refinancing activities and lower interest income. Our first quarter adjusted tax rate was 19.8%, reflecting a benefit from US R&D tax credits and a favorable mix of earnings.

First quarter adjusted EPS was $1.42, up approximately 40% from $1.02 in the prior year period. We are well positioned to continue driving strong earnings growth, reflecting the strength of our durable recurring revenue model, our compelling top-line trajectory, and the operating leverage we are generating.

Turning to cash and liquidity, during the quarter, we repurchased approximately 1.25 million shares for $300 million. We ended the quarter with $480 million in cash and the full $500 million available under our credit facility, and we generated approximately $90 million in free cash flow in Q1, reflecting our strong operating performance in the quarter.

Now turning to our outlook for the second quarter and full year 2026. For the second quarter, we expect Omnipod revenue to grow 21% to 23% and total company revenue to grow 20% to 22%.

On a reported basis, foreign currency is expected to contribute approximately 100 basis points of benefit to both growth rates. In the US, we expect Omnipod revenue growth of 18% to 20%.

This guidance reflects approximately $10 million of revenue that shifted into the first quarter, creating a 200 basis point headwind to second quarter growth. Internationally, we expect Omnipod growth of 28% to 30%.

While growth remains strong, as we discussed last quarter, we expect the pace to moderate as we anniversary successful launches from last year. On a reported basis, foreign currency is expected to provide a favorable impact of approximately 200 basis points on international growth.

Turning to our full year 2026 outlook, we now expect total Omnipod revenue growth of 22% to 24% and total company revenue growth of 21% to 23%, reflecting our strong start to the year. We expect foreign currency to provide a favorable impact of approximately 100 basis points for the full year.

For US Omnipod, we continue to expect our revenue to grow 20% to 22%. We expect year-over-year growth in US new customer starts for the year, positive pricing, and similar utilization trends.

We do expect retention rates to decrease modestly as our Type 2 customer base continues to grow, which is why we're investing in programs focused on improving onboarding, engagement, and long-term retention. For international Omnipod, we now expect 2026 revenue to grow 26% to 28%.

On a reported basis, we expect a favorable impact of approximately 300 basis points from foreign currency. We expect year-over-year growth in international new customer starts for the year as we penetrate further in current markets and expand Omnipod 5 into new markets.

Omnipod 5 is now available in 19 countries, and we will continue to broaden our reach and plan to enter Spain in the second half of 2026. While volume remains the primary driver of our international revenue growth, our guidance also reflects a benefit from positive price mix realization as customers continue to transition from Omnipod DASH to Omnipod 5.

Overall, our international growth guidance assumes similar utilization levels and improved retention for 2026 relative to 2025. Turning to 2026 operating margin, we continue to expect approximately 100 basis points of operating margin expansion for the full year, driven by strong top-line growth and ongoing gross margin expansion while funding a meaningful step-up in R&D and continued investments in sales and marketing offset by leverage in G&A.

I would note this outlook reflects the E&O costs we absorbed in the first quarter as well as incremental raw material and shipping costs driven by the ongoing conflict in the Middle East. Looking at a few items below our operating income, we expect 2026 net interest expense to total approximately $40 million, an increase of approximately $15 million, primarily due to lower interest income.

We now expect our 2026 non-GAAP tax rate to be in the range of 21% to 22%, reflecting the lower Q1 tax rate, favorable mix of earnings, and improved utilization of foreign tax credits. Based on these factors, we continue to expect adjusted EPS to increase by more than 25% in 2026.

We expect free cash flow to be approximately flat from 2025 levels, supported by robust growth and continued margin expansion, partially offset by a ramp-up in capital expenditures to support our continued global manufacturing expansion plans. To close, we're executing against a clear framework focused on delivering top-tier growth, margin expansion, and increasing free cash flow.

This approach underpins durable, long-term value creation while enabling us to expand access to Omnipod for people living with diabetes worldwide. With that, operator, please open the call for questions.

Thank you. Good morning, and appreciate you taking the questions here.

Maybe I will start with a strategic one and then go on to the financials. Ashley, I think you've been in the role now just about a year.

Maybe you could help frame the past year from your observations here. What's gone in line with your expectations, what's gone better, where are the areas where you're focused, and how are you kind of framing Insulet now that you've been in the role 12 months?

Thank you, David, for joining. It was just last week I marked my one year, and I would say that I'm absolutely more confident now than Insulet's potential than a year ago.

Us really as this high-growth medtech innovator doubling revenue over the past couple of years. I would say first and foremost, I'm preserving what makes us so special.

It's this culture of remarkable patient focus, entrepreneurial spirit, and really strong competitive moats, and really just focusing around how we enhance our capabilities to really double the business once again. Maybe it's just helpful to share some of the areas that we've been getting after as a team to unlock more value.

I would first start with innovation, and this is about doing things in parallel and at pace to continue our role as the tech leader. Let me give you examples.

It's really about being first in line to integrate day one with sensors like we're doing with the Dexcom 15-day and we will do with Abbott's upcoming dual analyte sensor. Algorithms, David, we were slow out of the gate continuously to improve our algorithms.

We've addressed that now, and we have three algorithm improvements over the next three years. Second is really about international and driving profitable growth globally.

I'm a big believer in going deeper in core markets that matter most versus going broader at this stage. The UK is a great example of this.

We're several years in the OP5 launch; this quarter we posted record NCS. The third is about our commercial engine and being famous not just as a tech leader, but as a commercial engine.

We have our second sales force expansion we've done in the past 12 months. It's happening this quarter.

As I've been consistently saying, it's really upskilling our force to sell clinically. The fourth is really about strengthening our unbelievable foundation on operations as we scale globally.

Costa Rica is a really good example of this. We just put in the foundation this quarter.

We'll be ready to have a watertight building by year-end and go live in 2029. Obviously it's all about people.

I came here and there was a remarkably talented team, and I'm just supplementing that team with some new leaders that have run bigger things and know how to scale. Collectively, we can get after doubling the business again.

This is what gives me confidence that we're going to continue to grow the category, serve more Podders, and really importantly, continue to increase our earnings power. You had a second question, David?

Yes, thank you. Appreciate all the perspective there, and that does kind of segue to my second question.

If you take kind of Q1 performance and the second quarter guidance into consideration, the outlook implies kind of high-teens growth in the back half of the year. Can you help us unpack that a little further on a geographic basis and your confidence in does the 20% LRT guidance as you exit 2026 potentially below that level and maybe perhaps there's some conservatism in the outlook given the timeline where we are in the year?

David, good morning, it's Flavia. I'll take that one.

To your point, yes, the midpoint of the guidance will imply second half growth in the high teens. I would first start by saying we're still seeing very, very strong performance in both the US and internationally.

As you saw, we just raised our guidance for international and the total company right now. Last year, there were a different and you tried you asked me to unpack between the two regions, in the US, last year we saw the opposite impact with comps playing a role in how this year first half second half compares to last year first half second half.

In international, we're going to continue having favorable impact of price mix realization, but it's going to be at a more more moderate pace as we increase penetration of Omnipod 5 in our international markets. When we look at the comps, I do think it's also important to look at dollars of growth.

When you look at this year in total year, we're actually going to be in line at the midpoint of the guidance with the same level of dollar growth that we delivered last year. The first half second half is going to be different, but the primary driver of that is actually currency.

If you look at that and look at the numbers on a constant currency basis, we had, the currency playing a role in the second half of 2025 that was a tailwind, and the first half of 2026 again as a tailwind. When you adjust for those things, the first half second half phenomenon gets a little bit more smooth, I would say.

Importantly, let me close where where your question was leading to, which is how does this play out in terms of our outlook for next year and beyond that we we shared with all of you at the LRP on the sustainability of our 20%? We feel very, very confident in our ability to drive that 20%.

What gives us that that confidence are the innovation and commercial catalysts that we're going to continue to execute. This year we're launching Libre 3+, which as you saw in our prepared remarks, expands our TAM by another 450,000 people with diabetes.

We have the algorithm enhancements. Ashley talked about the ones we're launching this year.

We're going to continue with Omnipod 6 next year and then fully closed loop in 2028. Then commercially, in addition to, leaning further on cleaning selling clinically and competitively, Ashley also just mentioned that we're going to be expanding our sales force this quarter.

As you can imagine, the full benefit of that expansion is really only going to be felt mostly next year. We do see that as another tailwind.

Internationally, similarly, those new product introductions are also going to have a benefit. We're going to launch L3 Libre 3+ in Germany and Canada.

These are two markets where there's no Abbott sensor and so that that are compatible with our our product. That again is another expansion of our serviceable market.

In addition to that, we're going to continue to to execute on our playbook of increasing access. You saw us just get the benefit of that for Canada this year with expansion of of coverage in additional provinces.

We just launched in the Middle East. We're going to be launching in Spain in the second half.

Again, we feel very, very confident that we have the right innovation and commercial levers to continue to support the 20% growth that we put out.

Thanks, Flavia.

Oh great. Thanks for taking the questions, and apologize for the background noise, I'm on a train right now.

I want to follow up on that last question, Flavia. As we think about similar dollar growth this year, that does imply deceleration as the sales base gets lower, and you did mention you're going to be exiting sub-20% in the US in the second half this year.

I think the question a lot of investors have is, how do you maintain that 20% growth rate over the LRP if you're decelerating into year-end and dollar growth is not increasing year-over-year? Maybe just fill us in on the gaps about 2027 and how that improves, and then I have a follow-up.

Robbie, I think, going back to what I just articulated, we will continue to drive the 20% with the innovations that we're launching. In 2027, we do have Omnipod 6 and the full benefit of the sales force that we're expanding this year that will be a tailwind.

I think, Robbie, just maybe what's helpful is kind of our philosophy of how we set guidance. A year ago, I came in and we got the team together, we've refined our strategic plan, we racked and stacked a whole portfolio of growth opportunities, and this led us to really a strengthened conviction in the untapped market opportunity.

Flavia was talking about the high TAM, low penetration. Quite frankly, our proven track record of unlocking that growth.

This led us to really raise our ambition as a company, which we shared at our IR Day, which is the first one we've done in 10 years, in November. We shared our strategies, our financial algorithm, and then we set our financial target accordingly.

Our goal is to outperform, and our quarter one results reflect this, along with our increasing full year outlook for the year. This is just really good momentum, and it gives us confidence in our commitments that we shared at our LRP.

Great. Maybe a quick follow-up.

You talked about a slowing market on seasonality and new patient starts in first quarter. I guess two parts.

One, what do you think the market grew? I know it's hard to give an answer without everybody else reporting yet.

What do you think it grew? Why was it more seasonal than usual?

How do you think your new patient starts US/OUS did in first quarter?

Obviously we don't have the market. The market exited, I would tell you, '24 and '25 at an accelerated rate versus prior years.

We're encouraged with the continued momentum. Listen, quarter one started off slow because we had higher than usual quarter one seasonality.

We attribute this to the reset of deductibles and potentially the ACA transition. Sequentially every month, we've been getting better.

I feel really good coming out of April as we look to quarter two and for the full year.

Hey, I wanted to ask about the Type 2 retention comps. Just kind of curious what you're seeing there, why kind of call it out falling and then when you think about the kind of the Type 2 opportunity, is kind of this next kind of 5 to 10 points of the penetration curve going to be harder to get than the first few points what you've got over the last year?

Just kind of curious how the Type 2 ramp is going.

Thank you, Travis. Our Type 2 momentum remains strong.

Our new customer starts in Type 2 grew meaningfully both year-over-year in the quarter, despite this Q1 seasonality that I spoke about. When we look at our customer base, we expanded both sequentially as well as year-over-year.

We're very much, Travis, at the early innings of this. I'd say we're at about 5% penetration, and CGM is around 55%.

We are actively preparing for a highly transformative launch where we're going to be sharing our feasibility data at the upcoming ADA called EVOLVE, which we've just enrolled our first patient last week. This will be what I call the industry's first truly fully closed-loop system for Type 2.

What do I mean by that? It's as CGM-like as you can get.

You put it on, no bolus, no user interaction, no settings, which unlocks the whole primary care physician audience, and really Uber-user consumer-friendly training. We've specifically designed our fully closed loop to unlock that huge TAM in Type 2 where they need it to be a CGM-like experience.

What about the retention piece?

I would say, listen, we have healthy retentions, we're not seeing any meaningful change year-over-year. We're getting to know this market, and I would say we're innovating our customer experience model, but from an aggregate basis our total company, we still have about 90% retention.

Travis, I would just say, I think you're alluding to my prepared remarks, I talked a bit about a slight deterioration in the US as we continue to expand into Type 2. This was very much in line with our expectations.

It is a different population, and the retention or attrition is exactly what we expected it would happen. We're pleased also to see that internationally, the retention actually, as we launched Omnipod in additional markets, has improved meaningfully.

On a total company basis, as Ashley said, retention remains very stable.

Okay. Then what percent of the new starts were Type 2 this quarter?

I think I missed that. Then when you think about the seasonality comments, is there any impact on the seasonality from the Type 1, Type 2 mix or kind of the macro?

Just kind of curious to follow up on the seasonality comments.

No, I think, listen, Travis, we had really healthy, I told you, total year-over-year growth. We experienced some softness in Q1 as a slower start for NCS.

Customer base is strong. I often get asked the question about Type 2, and I told you we've got really strong momentum.

I always can get asked about the GLPs: is that slowing down the progress in Type 2s? We did not observe an impact from increased GLP use on Type 2s' NCS this quarter.

I've always been sharing that we think that GLP-1s are very complementary to AID therapy, not competitive. It's, in fact, what we studied in our SECURE-T2D trial.

We see diabetes as a chronic, progressive disease, and nobody's been able to show that you can reverse beta-cell decline. Once you get on insulin, AID is really the standard of care per the ADA.

We look again at this huge TAM of 5.5 million people with Type 2 diabetes using insulin, and yet only 5% or less are using AID. We really look to unlock this right now and really really drive accelerated penetration when we have our fully closed loop launching in 2028.

Go ahead, Eric.

Travis, just to build on the numbers, the split of Type 1, Type 2 NCS was about 40% Type 2 NCS in the quarter, with similar seasonality seen in Type 1 and Type 2, ever so slightly more in Type 2, but consistent across the two segments.

Good morning, thanks for taking the question. I'll just keep it to one, Ashley.

I'm going to try to ask the competition question a little bit differently maybe than it's been asked before. We understand you believe it'll be hard for competitors to manufacture a tubeless pump or ramp the manufacturing, but I don't think you're saying that there won't be any tubeless competition in the future.

My question is, as your share of tubeless pumps declines from 100% today, just mathematically has to go down if there's competition, what offsets that to maintain your 20% growth goal? Is it faster overall pump market growth, or is it a greater shift from tubed to tubeless pumps, or both?

Thanks.

Thanks, Larry, for the question. The short answer is this is not a market share trading; this is about bringing new people into the category and the category expanding as a whole.

We're the market leaders, and we have a substantial distance versus the others, and I fully expect us to sustain share leadership. I was talking about we have no intention of ceding our tech leadership.

Next year, we're going to be on our sixth-generation Omnipod while others attempt to come out with their first. We know there's been a history of the competition trying to work on tubeless solutions for decades, which really underscores how hard it is, how complex it is to bring these highly disposable devices to market.

There's really a graveyard of a lot of failed attempts. We have a head start of really mastering how to develop and manufacture at scale, and this has given us a remarkable cost advantage and scale advantage, and we've got the earnings power to keep growing.

I think what's really important in this category is to understand that when new entrants enter, all boats rise. This increased promotion and the increased awareness will accelerate category expansion, which is exactly what we're seeing in the Type 2.

When you look back from four years ago, we had about 60% of patients coming from MDI into the AID category, and that number is now 80%. The category is expanding.

Great. Thanks so much for taking the questions.

I'll ask them both up front. I hate to beat this dead horse on new customer starts in Q1, Ashley, but I'm going to.

You've got a bunch of new competitors in the pharmacy channel. I just want to make sure there wasn't any kind of disruption, maybe early in the quarter as they were pushing on the pharmacy side, to sort of make it more difficult for you to get patients through the pharmacy channel, and that's why you saw a little bit of softness.

Then the second question is, there's a lot of investor consternation around the recall. Can you just frame up what you're seeing in the marketplace or from your customers in terms of the recall and the impact it's had on the business and then ability to add new patients?

Thanks.

No. Thank you, Matt.

Let me first be very clear, in quarter one, we don't think price had an impact. In fact, US pricing for us was positive in quarter one, and we expect this to continue for the full year.

What we've been seeing as others have entered the pharmacy channel, pricing and rebate behavior has been really rational and disciplined. We are not seeing significant discounting relative to the norm.

Our strategy is about creating durable, high-quality access with broad affordability, we are not going to trade long-term value for short-term positioning. I think what's really important to understand that maybe not fully appreciated is the significant size and scale that we benefit from.

Our volumes are multiples larger than the nearest competitor, and we don't expect that dynamic to change now or in the foreseeable future. You put that coupled with we're the number one prescribed brand, and we are the number one requested, and this is what gives us confidence for pricing going.

Important, but we still lead with a competitive advantage there. Let me go to your second question, which is about quality and our recent medical device correction.

I would say, hey, listen, in our industry, field actions are part of being in a healthcare industry, but it was an absolute tough moment for us. Patient safety is always our number one priority.

We're monitoring and we're investigating customer complaints routinely. I am proud with how our team rapidly responded to the voluntary medical device in March.

We do not believe that the medical device correction did have an impact on NCS in the quarter. As I discussed, I believe the slower start was really due to the broader quarter one seasonality and the reset of the deductibles.

Now, last week was another tough week with the FDA updating its communication about our MDC to reflect our April 10th update and misreported MDRs as SAEs. Listen, I know this created a bunch of confusion, and we're really not happy about that.

What's important to know, though, is no additional adverse events from the MDC have been reported since the April 10th update. If anything, taking a step back, I think this really enunciates the high level of complexity of manufacturing sophisticated, disposable electromechanical devices at scale.

In our industry, it's not possible to eliminate all risk, but what matters most is how issues are identified and addressed. In this case, we got after it early, we've implemented targeted corrective actions, and we are going to continue to strengthen and invest in our quality systems and operating controls.

Thank you. Good afternoon or good morning, everyone.

Ashley, I just wanted to follow up on that pricing comment. You said net pricing was up in the US in 1Q.

I just want to make sure that's net, that's not a WAC comment, that's actually net of rebates up in 1Q. It sounds like you're expecting that to be true for the year as well.

Just wondering, we're hearing from a couple of our other companies that we speak with that they're expecting pharmacy pricing next year on a net basis to also be up again in '27 over '26. I know that's hard to predict at this point and you won't know until later this year, but as we're kind of trying to set up our models for the next year or two, would you still build in kind of flattish pharmacy pricing in the US market over the next couple of years?

Would that still be kind of how you'd guide us as we build our models over the next couple of years?

I would say consistent with our Investor Day, Jeff, we expect pricing to be positive over the next three years, and quarter one is a data point, and we expect that to continue in full year '26. Again, it speaks to just the strength of the clinical and then economic value proposition that AID as a category has for payers and for PBMs.

Okay. Then again, just to confirm, that's net, not WAC, you're talking?

It is net, Jeff.

Okay. Thank you.

Then just on Type 2, I just want to make sure I understand the retention and utilization comments you're making on the US. Utilization was stable, retention maybe under a little bit of pressure.

Is that to imply that if I'm a Type 2 patient going on Omnipod 5, I'm using it every day or pretty much normally like a Type 1, but just more of those Type 2 patients are trying it for three months or six months and then saying, "Maybe it's not for me"? Utilization, when I'm an O5 user, is stable, but more of those Type 2s maybe dropping out after three or six or nine months or whatever, not sticking with it?

Is that the way to think about what you're trying to communicate today? Thanks.

No, thanks for the question. I think what we're learning in the patient journey of being Type 2, again, we're sourcing the predominant amount from MDI, is a little bit of the ongoing support it takes them to get them onto Pod and the reinforcing support that we need to do really early on.

Then it smooths out, and really there's a learning agility that has to happen early on. Then what we're finding is really good brand loyalty and really good retention over time.

It is a bit of a different class than what we've seen in Type 1, but overall very encouraged with the progress that we've had about 18 months into this launch. Do you want to add anything, Eric, to that?

No, I think exactly as you described. We're seeing, as you laid out, utilization for Type 2 stable, pretty similar to Type 1, and retention, the drop-off particularly early, getting folks accustomed to wearing the product.

As Ashley described, is a little bit different. We're learning and evolving our model of how we get folks successfully on so that they can stay enduring, happy, successful customers on Omnipod.

Good morning, and thanks for taking the question. Just on the 2Q international growth guide, it implies a bit more of a deceleration that I would have thought given what was obviously a very strong 1Q.

Comps not too much different, I guess my question is: one, is there any stocking impact in 1Q that maybe related to some of the new international countries? Then two, just outside of the comp, what weighs on 2Q international growth?

Thanks.

Jayson, I'll take that. In international, while, as I said, price mix realization will continue to be positive, the pace of it will moderate a little bit as we sort of anniversary some of these launches and continue the evolution of our installed base from DASH to Omnipod 5.

The dollars will continue to be sequentially increasing quarter-over-quarter on a constant currency basis, but the growth rate, as you pointed out, will decelerate.

Great, thank you so much. I just had a quick follow-up.

The $10 million in revenue that shifted into Q1, can you just elaborate on what the nature of that was? Then with respect to my question, Ashley, I was hoping you could talk a little bit more on the commercial front.

You guys are strengthening your message around the algorithm time in range, you've called out three algorithm launches in the next three years, how meaningful are those upgrades? The US sales force expansion, any way to think about the pace of that, and should we expect you to continue to do that throughout '26?

Thank you.

Thank you, Shagun. Let me kind of start with your first one.

We had about $10 million just from some inventory that was coming in quarter one, it went actualized, it'll come out of quarter two. You'll see, quarter two, we have a really strong call.

We had 29% growth last year, we do have a stronger comp, but we see momentum continuing in the US. I think it's important that I just spend a brief moment of you've heard me talk a lot about what are we doing commercially to strengthen our engine.

There's a couple things that I would share, Shagun, to your point. Number one is investing in our field.

It's our number one P&L item and making sure that we are upskilling our force to sell clinically in addition to their beautiful passion of selling our disruptive form factor. We've just retrained and retested all of our reps.

We actually have the largest sales rep force in the category. Then we are expanding our call points with improved targeting and segmentation and improving our reach and frequency with an expanding prescriber base.

To your point about clinically, they've gotten really good momentum of selling our optimized setting, improving time in range. They're going to be out there this quarter talking about our new lower set point at 100 as well as keeping people more in automated mode.

We're integrating with Libre 3+, which brings with us 450,000 users from MDI that are on Libre 3 who are not on Omnipod into our portfolio. You can look at our website, Shagun, I would say, where we're listing all of our updated clinical evidence relative to what's available in the industry, please take a look at that.

Then obviously maintaining our competitive advantage in market access and affordability is a second lever. The third, you heard me talk about this in my remarks, is really about getting our clinical performance out there.

We've doubled the amount of our professional events in the past quarter. In fact, we've significantly invested.

In 2020, we were around 50 a year; we elevated that to about 100, to about 150 a couple years ago. We executed 500 peer-to-peer education programs in 2025, really all about clinical performance.

The last really is about this brand. It was really cool to see us kind of being dropped into culture on Scrubs.

We got a lot of feedback of making the category really accessible to a lot more people, and this is what we will continue to do to grow the category. Thanks for the question, Shagun.

Hi, good morning, thanks for taking the question. I wanted to ask one on the tailwinds that you called out in '27, specifically on Omnipod 6.

Do you expect that launch, I guess, to drive just increased share gains and customer starts, or could you actually get price mix benefits from the launch of Omnipod 6 as well?

Listen, this is going to be our sixth generation. It's really to continue to extend our leadership and deliver our role of continuing to build the category and bring people in from MDI.

It will have, Matt, our third algorithm improvement. Again, I come back to the simplicity.

If you're on MDI, how to keep it really simple. This new algorithm is going to have greater automation, it's going to have less bolusing, it's going to have a reduced user interaction.

It was designed exactly to bring more people into the category. We're going to have some of our data shared at the ADA coming up in June of our STRIVE, which will show about our clinical performance.

The fun thing maybe underappreciated as I would share is sensors have gotten really small, and our Omnipod 6 also has dramatic improvement in what we call over-the-air improvements so that people can wear it on multiple places of their body. We get a lot of feedback on that.

Importantly, we're also moving to a single pod chassis, which allows prescribers to only write one script versus two scripts regardless of your sensor, and it clearly has a big impact on our supply chain and simplification. Thank you for the question, Matt.

Listen, let me thank everybody for your questions and engagement. We are very encouraged by the momentum of the business that we're seeing, and we look forward to updating you on our continued progress.

Thanks so much.